Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome in Recurrent/Metastatic Head and Neck Cancer
NCT04902027Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2021
- Primary completion
- Oct 2023
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in head and neck squamous cell carcinoma (HNSCC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Adverse Events. Started Jul 2021; status: completed.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04902027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04902027.